The TOP trial, a phase three study focused exclusively on TP53-mutant EGFR-mutant non-small cell lung cancer, validated the FLAURA2 findings in this high-risk subset, showing a striking PFS benefit of 34.0 versus 15.6 months (HR 0.44) for osimertinib plus chemotherapy over monotherapy, with a favorable duration of response of 32.7 versus 15.9 months, though overall survival data remain immature.
The FLAURA2 phase three trial demonstrated that adding platinum-based chemotherapy to osimertinib significantly improved outcomes over osimertinib monotherapy in first-line EGFR-mutant non-small cell lung cancer, with a median PFS of 29.4 versus 19.9 months and a statistically significant overall survival benefit of 47.5 versus 37.6 months.
The COPERNICUS study, an ongoing phase two trial, evaluated amivantamab-based regimens in EGFR-mutant non-small cell lung cancer across two cohorts, first-line and post-osimertinib progression, with a key focus on implementing mandatory prophylactic skin and DVT regimens, resulting in dramatically lower rash rates (4% grade 3+) compared to the original MARIPOSA trial.
Panelists discuss the pivotal MARIPOSA trial, which examined combining amivantamab with lazertinib versus osimertinib monotherapy, showing improvements in progression-free survival (23.7 vs. 16.6 months), overall survival, CNS efficacy, and particularly strong benefits in high-risk subgroups such as TP53-mutant patients. Safety data from the trial highlighted the importance of prophylactic measures, especially for rash and other adverse events, noting that with current prophylaxis protocols, serious toxicity rates have been significantly reduced compared to the original study.
This opening section introduces the COPERNICUS study and frames it within the evolving treatment landscape for EGFR-mutated metastatic non–small cell lung cancer.
Misako Nagasaka, MD, PhD, summarizes the key takeaways: proactive AE management, CNS vigilance, and strategic sequencing as hallmarks of modern care for EGFR-mutant NSCLC.
The conversation shifts to how dual EGFR-MET inhibition reduces resistance mutations and molecular heterogeneity compared with osimertinib monotherapy.
The panel examines a 59-year-old woman with small brain metastases, addressing therapy selection to balance CNS control, survival, and quality of life.
Misako Nagasaka, MD, PhD, Dr. Nagasaka introduces the panel and outlines the session’s focus on applying new EGFR-mutated NSCLC data to practice, with emphasis on CNS control and toxicity prevention.
